retatrutide triple agonist glp-1 gip glucagon receptor Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide Obesity Treatment Shows Promising

doi: 10.1038/s41564-018-0306-4 453 CryanJFORiordanKJCowanCSMSandhuKVBastiaanssenTFSBoehmeMet al

Their review joins a couple of other recent ones in places like the American Journal of Sports Medicine and Sports Medicine Update

At Thrive Medicine Clinic in Houston Heights, we help adults understand their options with clear guidance, attentive monitoring, and a plan designed for long-term success

What benefits do patients gain from combining Wesper with GLP-1 therapies

Clinical evidence shows incremental improvement over microneedling alone, particularly on mature striae albae where re-initiating the healing response is more demanding

Your digestion then feels lighter and side effects decrease